Imricor Medical Systems (ASX:IMR) Research & Development: A$16.97 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IMR Imricor Medical Systems Inc ASX:IMR
43 GF Score
Price A$1.83
GF Value A$0.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Imricor Medical Systems Research & Development?

Imricor Medical Systems ASX:IMR 43 Research & Development is A$16.97 Mil as of Dec. 2025. GuruFocus rates ASX:IMR with a GF Score™ of 43/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Imricor Medical Systems's Research & Development for the six months ended in Dec. 2025 was A$8.12 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$16.97 Mil.

Imricor Medical Systems  (ASX:IMR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Imricor Medical Systems Research & Development Related Terms

Imricor Medical Systems Research & Development Historical Data

* Premium members only.

The historical data trend for Imricor Medical Systems's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems Research & Development Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 13.53 11.78 11.83 12.92 16.79

Imricor Medical Systems Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.98 5.72 6.92 8.85 8.12
ASX:IMR
43GF Score
Imricor Medical Systems Inc ASX:IMR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imricor Medical Systems Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$16.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$16.97 Mil mean?
Imricor Medical Systems (ASX:IMR) has a Research & Development of A$16.97 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Imricor Medical Systems and its competitors.
Is Imricor Medical Systems' Research & Development too high?
Imricor Medical Systems' current Research & Development is A$16.97 Mil. Overall, Imricor Medical Systems has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Research & Development compare to ABT and SYK?
Imricor Medical Systems' Research & Development of A$16.97 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Imricor Medical Systems and its competitors. Imricor Medical Systems's current Research & Development is A$16.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.83 — trading 1725% above its estimated fair value. The current Research & Development is A$16.97 Mil. Imricor Medical Systems' overall GF Score™ is 43/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Research & Development is A$16.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued. The current stock price of A$1.83 is trading 1725% above its estimated GF Value™ of A$0.10. GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.

Key valuation signals for ASX:IMR:

  • Research & Development: A$16.97 Mil
  • GF Value™: A$0.10 vs. price of A$1.83 (1725% above fair value)
  • GF Score™: 43/100 with 10 warning signs

No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imricor Medical Systems Business Description

Address 400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
43GF Score

Get the complete analysis for ASX:IMR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.83
Price
A$0.10
GF Value